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Abstract
The treatment of soft tissue tumors needs the coordinated adoption of surgery with radiation
therapy and eventually, chemotherapy. The radiation therapy (delivered with a linear accelerator)
can be preoperative, intraoperative, or postoperative. In selected patients adjuvant brachytherapy
can be adopted. The goal of these associations is to achieve tumor control while maximally
preserving the normal tissues from side effects. Unfortunately, the occurrence of local and distant
complications is still elevated. Electrochemotherapy is a novel technique that combines the
administration of anticancer agents to the application of permeabilizing pulses in order to increase
the uptake of antitumor molecules. While its use in humans is still confined to the treatment of
cutaneous neoplasms or the palliation of skin tumor metastases, in veterinary oncology this
approach is rapidly becoming a primary treatment. This review summarizes the recent progresses
in preclinical oncology and their possible transfer to humans.
Introduction
Achieving local tumor control in cancer patients is one of
the primary tasks of oncologists and is frequently cause of
serious concerns. In fact, lack of awareness, inadequate
screenings and the sudden onset of rapidly growing neo-
plasms often do not allow to eradicate cancer by using sur-
gery alone. Therefore, due to the advanced stage at the
time of diagnosis, cancer is preferentially treated with
multi-modality therapies. In humans, these combinations
have been tested through multi-institutional phase II and
III trials and usually consist of the association of surgery
and radiation therapy (either brachytherapy or radiation
beam) [1-6]. Chemotherapy is usually confined to an
adjuvant role for those cancers with high tendency to
metastasize (i.e. high grade sarcoma or breast cancer) or is
perfusionally administered in combination with hyper-
thermia for advanced disease [7-10]. However, the high
costs of these treatments as well as the side effects of these
procedures limit their widespread application [1,10,11].
Another crucial point when evaluating local therapies for
advanced neoplasms is the biological cost paid by the
patients. Sometimes the complications of aggressive sur-
gery and radiation therapy may result in a poor quality of
life. The most commonly reported side effects of radiation
therapy are: 1) gradual side-effects, usually dose-depend-
ent (local fibrosis, necrosis, nerve damage etc.) and 2) the
so called "statistically demonstrable side effects", also
known as "radiation induced tumors" [2,3].
The risk of side effects is particularly high when dealing
with aggressive malignant neoplasms (Grade III with high
mitotic rate). However, in case of large neoplasms that
involve deep underlying structures, preoperative radiation
therapy might be chosen in the attempt to shrink the
Published: 14 August 2009
Journal of Experimental & Clinical Cancer Research 2009, 28:114 doi:10.1186/1756-9966-28-114
Received: 14 June 2009
Accepted: 14 August 2009
This article is available from: http://www.jeccr.com/content/28/1/114
© 2009 Spugnini et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Experimental & Clinical Cancer Research 2009, 28:114 http://www.jeccr.com/content/28/1/114
Page 2 of 5
(page number not for citation purposes)
tumor volume and to reduce the satellite infiltrations [5].
Unfortunately the rate of local wound complication asso-
ciated with aggressive surgical management and radiation
therapy is still elevated [6]. The incidence of these side
effects cannot be reduced since several publications
pointed out a trend toward increased disease free interval
and survival in patients receiving multimodality treat-
ments [7,9,10].
Electrochemotherapy
A new cancer treatment that can achieve high rates of
remission without the associated problems of high finan-
cial and biological cost of previous procedures has been
explored over the past 15 years and called electrochemo-
therapy (ECT). It combines the administration of chemo-
therapy drugs with the application of permeabilizing
pulses having appropriate waveform in order to enhance
the captation of antitumor molecules by tumor cells.
Before its clinical adoption, in vitro studies showed that
the application of high voltage, exponentially-decaying
electric pulses to cells in suspension could induce "pores"
in the cell membrane, thus resulting in cross-membrane
flow of material or even in cell fusion if the cells were
closely located [12-14]. Later, researchers discovered that
electroporation could be instrumental to increase the
delivery of drugs and plasmids through the cytoplasmic
membrane by exposing animal cells in culture and plant
protoplasts to adequate electric pulses [12-15]. In a sec-
ond time, electroporation was used to improve the in vitro
cytotoxicity of specific anticancer agents [16,17].
The first and still most actively used chemotherapy agent
in ECT has been bleomycin. This drug can enter the cell
membrane only through specific protein receptors, since
its lipophobic nature prevents the simple diffusion, there-
fore resulting in slow and extremely limited uptake under
normal conditions [16]. The complex formed by bleomy-
cin and the membrane receptor is transferred within the
cytosol through endocytotic vesicles. In the nucleus bleo-
mycin rapidly causes DNA fragmentation, that is similar
to that induced by radiation [16,17]. The high toxicity of
bleomycin when it reaches the intracellular environment
is limited by its impaired diffusion (less than 0.1%
reaches its target in cultured cells) through the cytoplas-
mic membrane [16,17]. For these reasons, despite its ther-
apeutic potential, the use of bleomycin has been limited
in the clinical experience, until it has been shown that its
cytotoxicity could be significally enhanced by electropora-
tion, leading to a revival of this drug [17-22]. Another
drug whose uptake can be increased by this mechanism is
cisplatin (CDDP), however its captation is less influenced
by the concurrent application of electric pulses, conse-
quentially this agent has been less extensively investigated
[23].
Several electroporation protocols have been adopted,
mostly involving sequences of repeated decaying or
square single pulses until the desired number of permea-
bilizing electric stimulations was reached [12-18]. More
recently, a novel protocol involving the adoption of bursts
of biphasic pulses with selectable period of repetition has
been successfully used both in veterinary patients as well
as in humans [19,24-31]. This schedule offers advantages
in decreasing the morbidity of the treated animals and
humans as well as improving the clinical outcome [19,24-
32].
The exact mechanism of this therapy at the membrane
level is not yet well understood, however recently consist-
ent membrane changes have been shown by electron
microscopy, following the exposure to electric pulses of
melanoma tumors transplanted in mice [33]. Specifically,
the freeze-fracturing analysis "evidenced defects in the
dynamic assembly of lipids and proteins in both models,
which ended up with the formation of "areas with rough
structure" and intensive clustering of intramembrane pro-
teins" [33]. These changes are suggestive of lipid and pro-
tein alterations, of altered protein cohesion and, perhaps.
polarity, as well as of changes in lipid orientation within
the cell membranes. Finally, the intercellular flow of
microvescicle among cancer cells was disrupted following
the destruction of these organelles by the electric pulses,
probably inducing an impairment of cytokines and inter-
cellular signal pathway.
Results obtained in pets with spontaneously occurring 
neoplasms
Differently from other cancer investigations, electrochem-
otherapy has frequently conducted at the same time stud-
ies in rodents and in companion animals.
The first in vivo study involved the use of ECT as a rescue
protocol in cats with recurring soft tissue sarcoma after
adjuvant radiation therapy [18]. In that trial, cats were
randomized to receive bleomycin ± the implant of 30 ×
106 CHO cells (secreting interleukin 2) followed by the
application of square pulses. The study was completed by
a small cohort of untreated cats that acted as control. The
authors described only one partial response however, they
claimed a prolonged survival in 12 cats receiving ECT ver-
sus 11 untreated controls. This minimal response rate
could be partially due to the previous treatments that led
to the development of chemoresistance. In fact, it is
known that radioresistant neoplasms have increased DNA
repair which is one of the described mechanisms of resist-
ance to bleomycin as well, at least in cell lines [15].
After this preliminary investigation, two phase I/II studies
were conducted in companion animals; in the first a
cohort of dogs and cats were treated with intralesional cis-Journal of Experimental & Clinical Cancer Research 2009, 28:114 http://www.jeccr.com/content/28/1/114
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platin coupled with square electric pulses [23] while in the
second they received intralesional bleomycin driven by
trains of biphasic pulses [19]. The overall response rate of
this second investigation was 80% with a 40% of long
lasting remissions. This study evidenced that among the
treated neoplasms, canine hemangiopericytomas were
particularly responsive to this approach. This work evi-
denced two problems of ECT: the need of specifically tai-
lored electrodes for the therapy of soft tissue neoplasms
and the major obstacle to a smooth permeabilization rep-
resented by the high content of connective tissue within
solid tumors [24]. Currently, ECT is preferentially
adopted as single modality only for tumors very suscepti-
ble to electroporation such as melanomas and perianal
adenomas [34-36] or relatively small in size and easily
accessible like sun-induced nasal carcinomas [29]. In
selected patients with cutaneous epitheliotropic and non-
epitheliotropic lymphoma this therapy can lead to suc-
cessful palliation or even extended local control and, con-
sequently, survival [37].
After the development of novel electrodes [25], several
phase II studies were conducted in our Institution to eval-
uate the potential of ECT as adjuvant treatment after sur-
gical cytoreduction of bulky tumors mimicking the
protocols of intraoperative radiation therapy [38].
A preclinical study involving cats with soft tissue sarco-
mas, evaluated the potentials of intraoperative and post-
operative ECT [26]. Cats were randomized to the
following groups: surgery single modality, surgery plus
intraoperative ECT and surgery plus postoperative ECT.
The study underlined the significant advantage offered by
adjuvant ECT in terms of local control and overall survival
compared to surgery alone. Time to recurrence was 12 and
19 months for the intraoperative and postoperative
cohorts respectively, while the tumors treated with surgery
alone recurred within an average of 4 months. The results
compare favorably with those of the current veterinary
oncology therapies. The difference in local control times
can be ascribed to the decision to enroll in the intraoper-
ative group cats with rapidly growing neoplasms, leading
to greater electroporation fields. One critical advantage of
this technique is the possibility to repeat the treatment in
selected patients experiencing local recurrence without
the side effects of re-irradiated tissues [26].
A similar study in 22 dogs with soft tissue sarcomas, pref-
erentially treated with a postoperative protocol, yielded a
median time to recurrence of 730 days with a 95%
response rate, and again hemangiopericytoma showed to
be extremely sensitive to ECT, data confirmed by results
obtained in cats as well [27,39]. The side effects of veteri-
nary patients treated with adjuvant ECT were confined to
local inflammation and occasional wound dehiscence
[26,27].
Concurrently, adjuvant ECT has been tested in a cohort of
28 dogs with mast cell sarcomas, resulting in a response
rate of 85% and a mean time to recurrence of 52.7 ± 6.5
months, moreover the authors reported that at the time of
writing the median time to recurrence was not reached
yet, since 24 of the patients were still disease free [28].
Two patients experiencing marginal recurrence were suc-
cessfully treated with a minor surgery combined with a
single application of electrochemotherapy [28]. The use of
Table 1: Summary of treatment outcome for cancer pets receiving electrochemotherapy
Drug Species N° of patients Tumor Type Response References
B Cats 12 STS SD 7 months 18
B Dogs and cats 16 Various 80% CR+PR 19
CDDP Dogs and cats 7 Various 84% CR 23
B Dogs and cats 5 Various CR > 24 mo 25
B Cats 58 STS Median time to recurrence: 12–19 mo 26
B Dogs 22 STS Median time to recurrence 24 mo 27
B Dogs 28 MCT 82%CR > 22 mo 28
B Cats 9 SCC 78%CR> 3 mo 29
B Cats 1 Ganglioneuroblastoma CR > 15 mo 30
B Dogs 10 Melanoma 70% CR> 6 mo 34
CDDP Dogs 1 Anal Melanoma PR 3 mo 35
B Dogs 12 Perianal tumors 83% CR 36
B Dogs and Cats 6 Lymphoma 100% CR 1 wk to 36 mo 37
B Cats 1 HPC CR> 12 mo 39
CDDP Dogs 1 Anal sac carcinoma CR> 18 mo 40
CDDP Cats 1 Fibrosarcoma CR 3 mo 41
Mitoxantrone Dogs 1 Metastatic carcinoma CR > 6 mo 43
B Bleomycin; CDDP Cisplatin; CR Complete Remission; HPC Hemangiopericytoma; MCT Mast Cell Tumors; PR Partial Remission; SCC Squamous 
Cell Carcinoma; SD Stable Disease; STS Soft Tissue Sarcoma.Journal of Experimental & Clinical Cancer Research 2009, 28:114 http://www.jeccr.com/content/28/1/114
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ECT is not strictly limited to superficial neoplasms: there
is also some evidence that trains of biphasic pulses can
improve the local control of incompletely excised deep
perianal tumors, with preservation of organ function
[35,36,40]. Caution should be exerted when adopting
ECT as a rescue in patients that failed radiation therapy. A
case report describes a severe radiation recall in a cat
treated with adjuvant radiation therapy for a recurring fib-
rosarcoma [41]. Interestingly, this cat has been locally
treated with cisplatin rather than bleomycin and perhaps
the reaction has been triggered by the local administration
of a platinum compound, since it is among the drugs
linked with this type of complication [42]. Table 1 sum-
marizes the results obtained in companion animals carry-
ing spontaneous tumors that have been so far treated with
electrochemotherapy.
Conclusion
ECT has proven to be a safe and efficacious therapy for the
local control of soft tissue neoplasms in companion ani-
mals, and its effectiveness is especially strengthened when
used in an adjuvant fashion through the generation of
trains of biphasic pulses [15,21-37,39-41,43]. ECT is cur-
rently being assayed for different spontaneous tumors in
companion animals showing promising results and iden-
tifying patterns of response and clinical [25-27] as well as
histopathological prognostic factors [31]. Further studies
are currently ongoing to evaluate new drugs and delivery
systems to improve the responses obtained so far, in par-
ticular mitoxantrone is a drug that is showing considera-
ble promise [43], also in view of its future applications to
human patients.
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